NorthWest Biotherapeutics Inc (NWBO)

[doingmybest]

Know-Fear, very logical, I agree, since it is a small trial that will enroll quickly since UCLA has a volume business given their reputation for treating GBM the best, even this small trial may be rich in knowledge gained looking at safety first with the CI and then the efficacy of both mono DCVax and combo DCVax and the CI, which is what most are waiting and hoping for. I think the possibility of extension of efficacy beyond mesenchymal, even if to a lesser degree, would be huge. Of course demonstrating a more robust mesenchymal response also would be great. But, I think the big question posed by Dr. LL is what can be done with proneural and classical phenotype tumors to improve therapy so much more, like mesenchymal tumors. Quite exciting, hopefully building on very positive current P3 data, even if mostly limited to mesenchymal responses, what a breakthrough DCVax-L can be.